NITROFURANTOIN MONOHYDRATE/ MACROCRYSTALLINE- nitrofurantoin monohydrate/macrocrystalline capsule

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Buy It Now

Active ingredient:

NITROFURANTOIN (UNII: 927AH8112L) (NITROFURANTOIN - UNII:927AH8112L), NITROFURANTOIN MONOHYDRATE (UNII: E1QI2CQQ1I) (NITROFURANTOIN - UNII:927AH8112L)

Available from:

Alvogen Inc.

INN (International Name):

NITROFURANTOIN

Composition:

NITROFURANTOIN 25 mg

Administration route:

ORAL

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

Nitrofurantoin capsules (monohydrate/macrocrystals) are indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus . Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin capsules (monohydrate/macrocrystals) and other antibacterial drugs, nitrofurantoin capsules (monohydrate/macrocrystals) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents

Product summary:

Nitrofurantoin capsules, USP (monohydrate/macrocrystals) are available as 100 mg opaque black and yellow capsules imprinted “(band) Macrobid (band)” on one half and “52427-285” on the other. NDC 47781-303-01  bottle of 100 Store at controlled room temperature 15°C to 30°C (59°F to 86°F). Rx Only

Authorization status:

New Drug Application

Summary of Product characteristics

                                NITROFURANTOIN MONOHYDRATE/ MACROCRYSTALLINE - NITROFURANTOIN
MONOHYDRATE/MACROCRYSTALLINE CAPSULE
ALVOGEN INC.
----------
NITROFURANTOIN CAPSULES, USP (MONOHYDRATE/MACROCRYSTALS)
To reduce the development of drug-resistant bacteria and maintain the
effectiveness of
nitrofurantoin capsules (monohydrate/macrocrystals) and other
antibacterial drugs,
nitrofurantoin capsules (monohydrate/macrocrystals) should be used
only to treat or
prevent infections that are proven or strongly suspected to be caused
by bacteria.
DESCRIPTION
Nitrofurantoin is an antibacterial agent specific for urinary tract
infections. Nitrofurantoin
capsules, USP (monohydrate/macrocrystals) is a hard gelatin capsule.
Each capsule
contains 100 mg of nitrofurantoin in the form of 25 mg of
nitrofurantoin macrocrystals
and 75 mg of nitrofurantoin monohydrate.
The chemical name of nitrofurantoin macrocrystals is 1-[[[5-nitro-2-
furanyl]methylene]amino]-2,4-imidazolidinedione. The chemical
structure is the following:
Molecular Weight: 238.16
The chemical name of nitrofurantoin monohydrate is 1-[[[5-nitro-2-
furanyl]methylene]amino]-2,4- imidazolidinedione monohydrate. The
chemical structure
is the following:
Molecular Weight: 256.17
INACTIVE INGREDIENTS: Each capsule contains carbomer 934P, corn
starch,
compressible sugar, D&C Yellow No. 10, edible gray ink, FD&C Blue No.
1, FD&C Red No.
40, gelatin, lactose, magnesium stearate, povidone, talc, and titanium
dioxide.
Meets USP Dissolution Test 8.
CLINICAL PHARMACOLOGY
Each nitrofurantoin capsule (monohydrate/macrocrystals) contains two
forms of
nitrofurantoin. Twenty-five percent is macrocrystalline
nitrofurantoin, which has slower
dissolution and absorption than nitrofurantoin monohydrate. The
remaining 75% is
nitrofurantoin monohydrate contained in a powder blend which, upon
exposure to
gastric and intestinal fluids, forms a gel matrix that releases
nitrofurantoin over time.
Based on urinary pharmacokinetic data, the extent and rate of urinary
excretion of
nitrofurantoin from the 100 mg nitrofurantoin
                                
                                Read the complete document